Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | Autologous HERV-E TCR transduced T cells |
Trade Name | |
Synonyms | Autologous CT-RCC-1 HERV-E-TCR-transduced-HLA-A11-restricted CD8+/CD34t+ T-cells |
Drug Descriptions |
Autologous HERV-E TCR transduced T cells are patient-derived T-cells that have been engineered to express a T-cell receptor (TCR) that targets an HLA-A-A11-restricted HERV-E peptide, which potentially results in increased anti-tumor immune response against HERV-E-expressing tumor cells and increased tumor cell killing (Annals of Oncology (2018) 29 (suppl_8): viii303-viii331). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C157344 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Autologous HERV-E TCR transduced T cells | Autologous HERV-E TCR transduced T cells | 0 | 1 |